P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO

Podobné jednotky

• Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
  Autor: Robert A. Brodsky, a další
  Vydáno: (2020-01-01)
• Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
  Autor: Antonio M. Risitano, a další
  Vydáno: (2020-10-01)
• Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
  Autor: Anita Hill, a další
  Vydáno: (2010-04-01)
• Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial
  Autor: Morag Griffin, a další
  Vydáno: (2024-11-01)
• Paroxysmal nocturnal hemoglobinuria and eculizumab
  Autor: Lucio Luzzatto, a další
  Vydáno: (2010-04-01)